BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation

N. Theodoropoulos, E. Wang, S. Penugonda, D. P. Ladner, V. Stosor, J. Leventhal, J. Friedewald, M. P. Angarone, M. G. Ison*

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

BK virus nephropathy (BKVN) is a recognized cause of graft failure in kidney transplant recipients. There are limited data on the epidemiology of BK virus (BKV) infection after alemtuzumab induction. By clinical protocol, the kidney transplant recipients at our center were screened with BKV plasma PCR monthly for the first 4 months posttransplant then every 2-3 months for 2 years. A single center retrospective cohort study of all kidney transplant recipients from January 2008 to August 2010 was conducted to determine incidence and outcomes of BKV infection. Descriptive statistics and Kaplan-Meier analysis was performed. Of 666 recipients, 250 (37.5%) developed viruria, 80 (12%) developed viremia and 31 (4.7%) developed BKVN at a median of 17, 21 and 30 weeks, respectively. Induction with alemtuzumab did not significantly affect incidence of BKVN. Increased recipient age, African American race, acute graft rejection and CMV infection were significantly associated with the development of BKVN in multivariate analysis. The incidence of BK viruria, viremia and nephropathy was not significantly different among kidney transplant recipients who received alemtuzumab induction compared to patients receiving less potent induction. This retrospective cohort study of 666 kidney transplant recipients shows that the incidence of BK viruria, viremia and nephropathy is not significantly different among kidney transplant recipients who receive alemtuzumab induction when compared to patients who receive less potent induction. See article by Hirsch et al. on page 136.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalAmerican Journal of Transplantation
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

BK Virus
Virus Replication
Kidney Transplantation
Viremia
Kidney
Incidence
Virus Diseases
Cohort Studies
Retrospective Studies
Kaplan-Meier Estimate
Graft Rejection
Clinical Protocols
alemtuzumab
African Americans
Renal Insufficiency
Transplant Recipients
Epidemiology
Multivariate Analysis
Transplants
Polymerase Chain Reaction

Keywords

  • Alemtuzumab
  • BK virus nephropathy
  • kidney transplantation
  • lymphocyte depletion

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

@article{1aec2790cf6442e7a5270422d863ecd0,
title = "BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation",
abstract = "BK virus nephropathy (BKVN) is a recognized cause of graft failure in kidney transplant recipients. There are limited data on the epidemiology of BK virus (BKV) infection after alemtuzumab induction. By clinical protocol, the kidney transplant recipients at our center were screened with BKV plasma PCR monthly for the first 4 months posttransplant then every 2-3 months for 2 years. A single center retrospective cohort study of all kidney transplant recipients from January 2008 to August 2010 was conducted to determine incidence and outcomes of BKV infection. Descriptive statistics and Kaplan-Meier analysis was performed. Of 666 recipients, 250 (37.5{\%}) developed viruria, 80 (12{\%}) developed viremia and 31 (4.7{\%}) developed BKVN at a median of 17, 21 and 30 weeks, respectively. Induction with alemtuzumab did not significantly affect incidence of BKVN. Increased recipient age, African American race, acute graft rejection and CMV infection were significantly associated with the development of BKVN in multivariate analysis. The incidence of BK viruria, viremia and nephropathy was not significantly different among kidney transplant recipients who received alemtuzumab induction compared to patients receiving less potent induction. This retrospective cohort study of 666 kidney transplant recipients shows that the incidence of BK viruria, viremia and nephropathy is not significantly different among kidney transplant recipients who receive alemtuzumab induction when compared to patients who receive less potent induction. See article by Hirsch et al. on page 136.",
keywords = "Alemtuzumab, BK virus nephropathy, kidney transplantation, lymphocyte depletion",
author = "N. Theodoropoulos and E. Wang and S. Penugonda and Ladner, {D. P.} and V. Stosor and J. Leventhal and J. Friedewald and Angarone, {M. P.} and Ison, {M. G.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1111/j.1600-6143.2012.04314.x",
language = "English (US)",
volume = "13",
pages = "197--206",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "1",

}

BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation. / Theodoropoulos, N.; Wang, E.; Penugonda, S.; Ladner, D. P.; Stosor, V.; Leventhal, J.; Friedewald, J.; Angarone, M. P.; Ison, M. G.

In: American Journal of Transplantation, Vol. 13, No. 1, 01.01.2013, p. 197-206.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation

AU - Theodoropoulos, N.

AU - Wang, E.

AU - Penugonda, S.

AU - Ladner, D. P.

AU - Stosor, V.

AU - Leventhal, J.

AU - Friedewald, J.

AU - Angarone, M. P.

AU - Ison, M. G.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - BK virus nephropathy (BKVN) is a recognized cause of graft failure in kidney transplant recipients. There are limited data on the epidemiology of BK virus (BKV) infection after alemtuzumab induction. By clinical protocol, the kidney transplant recipients at our center were screened with BKV plasma PCR monthly for the first 4 months posttransplant then every 2-3 months for 2 years. A single center retrospective cohort study of all kidney transplant recipients from January 2008 to August 2010 was conducted to determine incidence and outcomes of BKV infection. Descriptive statistics and Kaplan-Meier analysis was performed. Of 666 recipients, 250 (37.5%) developed viruria, 80 (12%) developed viremia and 31 (4.7%) developed BKVN at a median of 17, 21 and 30 weeks, respectively. Induction with alemtuzumab did not significantly affect incidence of BKVN. Increased recipient age, African American race, acute graft rejection and CMV infection were significantly associated with the development of BKVN in multivariate analysis. The incidence of BK viruria, viremia and nephropathy was not significantly different among kidney transplant recipients who received alemtuzumab induction compared to patients receiving less potent induction. This retrospective cohort study of 666 kidney transplant recipients shows that the incidence of BK viruria, viremia and nephropathy is not significantly different among kidney transplant recipients who receive alemtuzumab induction when compared to patients who receive less potent induction. See article by Hirsch et al. on page 136.

AB - BK virus nephropathy (BKVN) is a recognized cause of graft failure in kidney transplant recipients. There are limited data on the epidemiology of BK virus (BKV) infection after alemtuzumab induction. By clinical protocol, the kidney transplant recipients at our center were screened with BKV plasma PCR monthly for the first 4 months posttransplant then every 2-3 months for 2 years. A single center retrospective cohort study of all kidney transplant recipients from January 2008 to August 2010 was conducted to determine incidence and outcomes of BKV infection. Descriptive statistics and Kaplan-Meier analysis was performed. Of 666 recipients, 250 (37.5%) developed viruria, 80 (12%) developed viremia and 31 (4.7%) developed BKVN at a median of 17, 21 and 30 weeks, respectively. Induction with alemtuzumab did not significantly affect incidence of BKVN. Increased recipient age, African American race, acute graft rejection and CMV infection were significantly associated with the development of BKVN in multivariate analysis. The incidence of BK viruria, viremia and nephropathy was not significantly different among kidney transplant recipients who received alemtuzumab induction compared to patients receiving less potent induction. This retrospective cohort study of 666 kidney transplant recipients shows that the incidence of BK viruria, viremia and nephropathy is not significantly different among kidney transplant recipients who receive alemtuzumab induction when compared to patients who receive less potent induction. See article by Hirsch et al. on page 136.

KW - Alemtuzumab

KW - BK virus nephropathy

KW - kidney transplantation

KW - lymphocyte depletion

UR - http://www.scopus.com/inward/record.url?scp=84871720949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871720949&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2012.04314.x

DO - 10.1111/j.1600-6143.2012.04314.x

M3 - Article

C2 - 23136975

AN - SCOPUS:84871720949

VL - 13

SP - 197

EP - 206

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 1

ER -